{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:43:40Z","timestamp":1792701820597,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Beh\u00e7et\u2019s disease (BD) is a systemic variable vessel vasculitis that involves the skin, mucosa, joints, eyes, arteries, veins, nervous system and gastrointestinal system, presenting with remissions and exacerbations. It is a multifactorial disease, and several triggering factors including oral cavity infections and viruses may induce inflammatory attacks in genetically susceptible individuals. BD vasculitis involves different vessel types and sizes of the vascular tree with mixed-cellular perivascular infiltrates and is often complicated by recurrent thrombosis, particularly in the venous compartment. Several new therapeutic modalities with different mechanisms of action have been studied in patients with BD. A substantial amount of new data have been published on the management of BD, especially with biologics, over the last years. These important therapeutic advances in BD have led us to propose French recommendations for the management of Beh\u00e7et\u2019s disease [Protocole National de Diagnostic et de Soins de la maladie de Beh\u00e7et (PNDS)]. These recommendations are divided into two parts: (1) the diagnostic process and initial assessment; (2) the therapeutic management. Thirty key points summarize the essence of the recommendations. We highlighted the main differential diagnosis of BD according to the type of clinical involvement; the role of genetics is also discussed, and we indicate the clinical presentations that must lead to the search for a genetic cause.<\/jats:p>","DOI":"10.1186\/s13023-020-01620-4","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T19:04:21Z","timestamp":1614107061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["French recommendations for the management of Beh\u00e7et\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"name":"Collaborators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kone-Paut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Galeotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Gaudric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Kaplanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Piram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu-Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"issue":"12","key":"1620_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00234-003-1102-1","volume":"45","author":"G Akman-Demir","year":"2003","unstructured":"Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P. Cranial MRI in Beh\u00e7et\u2019s disease: 134 examinations of 98 patients. Neuroradiology. 2003;45(12):851\u20139.","journal-title":"Neuroradiology"},{"issue":"Pt 11","key":"1620_CR2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir G, Serdaroglu P, Tas\u00e7i B. Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group. Brain J Neurol. 1999;122(Pt 11):2171\u201382.","journal-title":"Brain J Neurol."},{"issue":"2","key":"1620_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09273948.2011.555592","volume":"19","author":"L Atmaca","year":"2011","unstructured":"Atmaca L, Boyvat A, Yal\u00e7\u0131nda\u011f FN, Atmaca-Sonmez P, Gurler A. Beh\u00e7et disease in children. Ocul Immunol Inflamm. 2011;19(2):103\u20137.","journal-title":"Ocul Immunol Inflamm."},{"issue":"6","key":"1620_CR4","first-page":"119","volume":"35 Suppl 108","author":"ED Batu","year":"2017","unstructured":"Batu ED, S\u00f6nmez HE, S\u00f6zeri B, Butbul Aviel Y, Bilginer Y, \u00d6zen S. The performance of different classification criteria in paediatric Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2017;35 Suppl 108(6):119\u201323.","journal-title":"Clin Exp Rheumatol."},{"issue":"11","key":"1620_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0035-3787(06)75121-9","volume":"162","author":"S Benamour","year":"2006","unstructured":"Benamour S, Naji T, Alaoui F-Z, El-Kabli H, El-Aidouni S. Neurological involvement in Beh\u00e7et\u2019s disease. 154 cases from a cohort of 925 patients and review of the literature. Rev Neurol (Paris). 2006;162(11):1084\u201390.","journal-title":"Rev Neurol (Paris)."},{"issue":"3","key":"1620_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong DLT, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335\u20139.","journal-title":"Br J Ophthalmol."},{"issue":"2","key":"1620_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10067-015-2890-5","volume":"35","author":"L Cantarini","year":"2016","unstructured":"Cantarini L, Vitale A, Bersani G, Nieves LM, Cattalini M, Lopalco G, et al. PFAPA syndrome and Beh\u00e7et\u2019s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. Clin Rheumatol. 2016;35(2):501\u20135.","journal-title":"Clin Rheumatol."},{"issue":"2","key":"1620_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5582\/irdr.2015.01007","volume":"4","author":"S Demirelli","year":"2015","unstructured":"Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet\u2019s disease. Intractable Rare Dis Res. 2015;4(2):70\u20135.","journal-title":"Intractable Rare Dis Res."},{"issue":"6","key":"1620_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733\u20137.","journal-title":"Semin Arthritis Rheum."},{"issue":"8","key":"1620_CR10","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong DLT, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2012;64(8):2753\u201360.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"1620_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281\u20136.","journal-title":"Clin Rheumatol."},{"issue":"6","key":"1620_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/ICU.0b013e32834bbe91","volume":"22","author":"C Evereklioglu","year":"2011","unstructured":"Evereklioglu C. Ocular Beh\u00e7et disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011;22(6):508\u201316.","journal-title":"Curr Opin Ophthalmol."},{"issue":"1","key":"1620_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191\u20137.","journal-title":"Clin Rheumatol."},{"issue":"3","key":"1620_CR14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol Chic Ill 1960. 2011;129(3):288\u201394.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"12","key":"1620_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, G\u00fcney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2006;244(12):1692\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"issue":"12","key":"1620_CR16","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis. 2008;67(12):1656\u201362.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"1620_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.20452\/pamw.4233","volume":"128","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Esatoglu SN, Yurdakul S. Considerations in designing and interpreting prevalence studies for Beh\u00e7et syndrome. Pol Arch Intern Med. 2018;128(3):148\u20139.","journal-title":"Pol Arch Intern Med."},{"issue":"4 Suppl 84","key":"1620_CR18","first-page":"S58","volume":"32","author":"E Interlandi","year":"2014","unstructured":"Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Beh\u00e7et\u2019s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58\u201362.","journal-title":"Clin Exp Rheumatol."},{"issue":"9","key":"1620_CR19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","volume":"261","author":"S Kalra","year":"2014","unstructured":"Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS, et al. Diagnosis and management of Neuro-Beh\u00e7et\u2019s disease: international consensus recommendations. J Neurol. 2014;261(9):1662\u201376.","journal-title":"J Neurol."},{"issue":"Pt 11","key":"1620_CR20","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","volume":"122","author":"D Kidd","year":"1999","unstructured":"Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Beh\u00e7et\u2019s syndrome. Brain J Neurol. 1999;122(Pt 11):2183\u201394.","journal-title":"Brain J Neurol."},{"issue":"6","key":"1620_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1464-410X.1991.tb15230.x","volume":"67","author":"Z Kirkali","year":"1991","unstructured":"Kirkali Z, Yigitbasi O, Sasmaz R. Urological aspects of Beh\u00e7et\u2019s disease. Br J Urol. 1991;67(6):638\u20139.","journal-title":"Br J Urol."},{"issue":"1","key":"1620_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/rheumatology\/keq324","volume":"50","author":"I Kone-Paut","year":"2011","unstructured":"Kone-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet\u2019s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology. 2011;50(1):184\u20138.","journal-title":"Rheumatology."},{"issue":"4","key":"1620_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0022-3476(98)70368-3","volume":"132","author":"I Kon\u00e9-Paut","year":"1998","unstructured":"Kon\u00e9-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Beh\u00e7et\u2019s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132(4):721\u20135.","journal-title":"J Pediatr."},{"key":"1620_CR24","doi-asserted-by":"crossref","unstructured":"Kon\u00e9-Paut I. Beh\u00e7et\u2019s disease in children, an overview. Pediatr Rheumatol [Internet]. d\u00e9c 2016 [cit\u00e9 15 nov 2018];14(1). http:\/\/www.ped-rheum.com\/content\/14\/1\/10","DOI":"10.1186\/s12969-016-0070-z"},{"issue":"6","key":"1620_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2015-208491","volume":"75","author":"I Kon\u00e9-Paut","year":"2016","unstructured":"Kon\u00e9-Paut I, Shahram F, Darce-Bello M, Cantarini L, Cimaz R, Gattorno M, et al. Consensus classification criteria for paediatric Beh\u00e7et\u2019s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958\u201364.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"1620_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jbspin.2018.11.003","volume":"86","author":"I Kone-Paut","year":"2019","unstructured":"Kone-Paut I, Georgin-Laviallec S, Galeotti C, Rossi-Semerano L, Hentgen V, Savey L, Saadoun D, Sarrabay G, Touitou I. New data in causes of autoinflammatory diseases. Joint Bone Spine. 2019;86(5):554\u201361.","journal-title":"Joint Bone Spine."},{"issue":"05","key":"1620_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0030-1269909","volume":"41","author":"J Metreau-Vastel","year":"2010","unstructured":"Metreau-Vastel J, Mikaeloff Y, Tardieu M, Kon\u00e9-Paut I, Tran T-A. Neurological involvement in paediatric Beh\u00e7et\u2019s disease. Neuropediatrics. 2010;41(05):228\u201334.","journal-title":"Neuropediatrics."},{"issue":"2","key":"1620_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.revmed.2013.10.332","volume":"35","author":"N Noel","year":"2014","unstructured":"Noel N, Drier A, Wechsler B, Piette J-C, De Paz R, Dormont D, et al. Manifestations neurologiques de la maladie de Beh\u00e7et. Rev M\u00e9decine Interne. 2014;35(2):112\u201320.","journal-title":"Rev M\u00e9decine Interne."},{"issue":"7","key":"1620_CR29","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/rheumatology\/ker449","volume":"51","author":"N Noel","year":"2012","unstructured":"Noel N, Hutie M, Wechsler B, Vignes S, Le Thi Huong-Boutin D, Amoura Z, et al. Pseudotumoural presentation of neuro-Behcet\u2019s disease: case series and review of literature. Rheumatology. 2012;51(7):1216\u201325.","journal-title":"Rheumatology."},{"issue":"3","key":"1620_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","volume":"129","author":"S Onal","year":"2011","unstructured":"Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis. Arch Ophthalmol Chic Ill 1960. 2011;129(3):288\u201394.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"7","key":"1620_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/key445","volume":"58","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Omoyinmi E, Standing A, Pain CE, Booth C, D\u2019Arco F, Gilmour K, Buckland M, Eleftheriou D, Brogan PA. Monogenic mimics of Beh\u00e7et\u2019s disease in the young. Rheumatology (Oxford). 2019;58(7):1227\u201338.","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"1620_CR32","first-page":"35","volume":"4","author":"R Penza","year":"1983","unstructured":"Penza R, Brunetti L, Francioso G, Tricarico A, Lospalluti M. Renal amyloidosis in a child with Beh\u00e7et\u2019s syndrome. Int J Pediatr Nephrol. 1983;4(1):35\u20137.","journal-title":"Int J Pediatr Nephrol."},{"issue":"7","key":"1620_CR33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","volume":"12","author":"D Saadoun","year":"2013","unstructured":"Saadoun D, Bodaghi B, Bienvenu B, Wechsler B, Sene D, Trad S, et al. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev. 2013;12(7):774\u201383.","journal-title":"Autoimmun Rev."},{"issue":"4","key":"1620_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.24393","volume":"61","author":"D Saadoun","year":"2009","unstructured":"Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A, et al. Cerebral venous thrombosis in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2009;61(4):518\u201326.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"1620_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","volume":"91","author":"E Seyahi","year":"2012","unstructured":"Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35\u201348.","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"1620_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00415-009-0145-6","volume":"256","author":"A Siva","year":"2009","unstructured":"Siva A, Saip S. The spectrum of nervous system involvement in Beh\u00e7et\u2019s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513\u201329.","journal-title":"J Neurol."},{"issue":"6","key":"1620_CR37","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","volume":"152","author":"SRJ Taylor","year":"2011","unstructured":"Taylor SRJ, Singh J, Menezo V, Wakefield D, McCluskey P, Lightman S. Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152(6):1059\u201366.","journal-title":"Am J Ophthalmol."},{"issue":"12","key":"1620_CR38","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, G\u00fcney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2006;244(12):1692\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"issue":"21","key":"1620_CR39","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1212\/WNL.0b013e318238edeb","volume":"77","author":"D Uluduz","year":"2011","unstructured":"Uluduz D, Kurtuncu M, Yapici Z, Seyahi E, Kasapcopur O, Ozdogan H, et al. Clinical characteristics of pediatric-onset neuro-Behcet disease. Neurology. 2011;77(21):1900\u20135.","journal-title":"Neurology."},{"key":"1620_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun."},{"issue":"6","key":"1620_CR41","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol Hoboken NJ. 2016;68(6):1522\u201330.","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"issue":"6","key":"1620_CR42","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1097\/MD.0000000000000494","volume":"94","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner F, Karadeniz A, Ylmaz S, Balkarl A, Kimyon G, Yazc A, et al. Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94(6):e494.","journal-title":"Medicine (Baltimore)."},{"issue":"8","key":"1620_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.70.8.589","volume":"70","author":"D Benezra","year":"1986","unstructured":"Benezra D, Cohen E. Treatment and visual prognosis in Beh\u00e7et\u2019s disease. Br J Ophthalmol. 1986;70(8):589\u201392.","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"1620_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/08820530500231953","volume":"20","author":"AA Bonfioli","year":"2005","unstructured":"Bonfioli AA, Orefice F. Beh\u00e7et\u2019s disease. Semin Ophthalmol. 2005;20(3):199\u2013206.","journal-title":"Semin Ophthalmol."},{"issue":"4","key":"1620_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.autrev.2016.01.003","volume":"15","author":"E Chan","year":"2016","unstructured":"Chan E, Sangle SR, Coghlan JG, D\u2019Cruz DD. Pulmonary artery aneurysms in Beh\u00e7et\u2019s disease treated with anti-TNF\u03b1: a case series and review of the literature. Autoimmun Rev. 2016;15(4):375\u20138.","journal-title":"Autoimmun Rev."},{"issue":"6","key":"1620_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/09273948.2012.713159","volume":"20","author":"AK Cingu","year":"2012","unstructured":"Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I. Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20(6):423\u20138.","journal-title":"Ocul Immunol Inflamm."},{"key":"1620_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2017.03.029","volume":"178","author":"A De Parisot","year":"2017","unstructured":"De Parisot A, Kodjikian L, Errera M-H, Sedira N, Heron E, P\u00e9rard L, et al. Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE). Am J Ophthalmol. 2017;178:176\u201385.","journal-title":"Am J Ophthalmol."},{"issue":"8","key":"1620_CR48","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong DLT, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 2012;64(8):2753\u201360.","journal-title":"Arthritis Rheum."},{"issue":"4","key":"1620_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C. Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol. 2005;50(4):297\u2013350.","journal-title":"Surv Ophthalmol."},{"issue":"3","key":"1620_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","volume":"45","author":"V Hamuryudan","year":"2015","unstructured":"Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, Ozguler Y, et al. Pulmonary artery involvement in Beh\u00e7et\u05f3s syndrome: Effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45(3):369\u201373.","journal-title":"Semin Arthritis Rheum."},{"issue":"6","key":"1620_CR51","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318.","journal-title":"Ann Rheum Dis."},{"issue":"8697","key":"1620_CR52","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease. Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet Lond Engl. 1990;335(8697):1078\u201380.","journal-title":"Lancet Lond Engl."},{"key":"1620_CR53","doi-asserted-by":"crossref","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD). The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol JEADV. 2014;28(3):338\u201347.","DOI":"10.1111\/jdv.12107"},{"issue":"4 Suppl 60","key":"1620_CR54","first-page":"S39","volume":"28","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Beh\u00e7et\u2019s disease in Japanese patients. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S39\u201344.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"1620_CR55","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH. Epidemiology of Beh\u00e7et disease. Ocul Immunol Inflamm. 2012;20(5):324\u201335.","journal-title":"Ocul Immunol Inflamm."},{"issue":"1","key":"1620_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60\u201376.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"1620_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.survophthal.2004.10.004","volume":"50","author":"JG Ladas","year":"2005","unstructured":"Ladas JG, Wheeler NC, Morhun PJ, Rimmer SO, Holland GN. Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol. 2005;50(1):27\u201347.","journal-title":"Surv Ophthalmol."},{"issue":"12","key":"1620_CR58","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, et al. Azathioprine in severe uveitis of Beh\u00e7et\u2019s disease. Arthritis Care Res. 2010;62(12):1733\u20138.","journal-title":"Arthritis Care Res."},{"issue":"1","key":"1620_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","volume":"91","author":"D Saadoun","year":"2012","unstructured":"Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Beh\u00e7et disease: a series of 101 patients. Medicine (Baltimore). 2012;91(1):18\u201324.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"1620_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.22500","volume":"57","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, et al. Epidemiology and clinical course of Beh\u00e7et\u2019s disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum. 2007;57(1):171\u20138.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"1620_CR61","first-page":"2878","volume":"33","author":"SM Shah","year":"1992","unstructured":"Shah SM, Spalton DJ, Taylor JC. Correlations between laser flare measurements and anterior chamber protein concentrations. Invest Ophthalmol Vis Sci. 1992;33(10):2878\u201384.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"1620_CR62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0974-9233.58425","volume":"16","author":"I Tugal-Tutkun","year":"2009","unstructured":"Tugal-Tutkun I. Beh\u00e7et\u2019s uveitis. Middle East Afr J Ophthalmol. 2009;16(4):219\u201324.","journal-title":"Middle East Afr J Ophthalmol."},{"issue":"4","key":"1620_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","volume":"52","author":"I Tugal-Tutkun","year":"2012","unstructured":"Tugal-Tutkun I. Imaging in the diagnosis and management of Beh\u00e7et disease. Int Ophthalmol Clin. 2012;52(4):183\u201390.","journal-title":"Int Ophthalmol Clin."},{"issue":"3","key":"1620_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380.","journal-title":"Am J Ophthalmol."},{"issue":"2","key":"1620_CR65","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","volume":"115","author":"P Yang","year":"2008","unstructured":"Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Beh\u00e7et\u2019s disease. Ophthalmology. 2008;115(2):312\u2013318.e4.","journal-title":"Ophthalmology."},{"issue":"5","key":"1620_CR66","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, T\u00fcz\u00fcn Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med. 1990;322(5):281\u20135.","journal-title":"N Engl J Med."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01620-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T15:10:04Z","timestamp":1724512204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01620-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":66,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01620-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"24 February 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IKP reports consulting fees\/meeting fees from Novartis, Abbvie, SOBI, LFB; speaking fees from Novartis, SOBI, Pfizer, Zeste Research, LFB; and research funding from Novartis. SB, ACD, CG, JG, GK, NN and DS reports no conflicts of interest. BB reports consulting fees\/meeting fees from Allergan, Santen, Abbvie, Alimera; speaking fees from Abbvie, Alimera. AM reports consulting fees\/meeting fees from Celg\u00e8ne and speaking fees from Roche-Chuga\u00ef. MP reports consulting fees\/meeting fees from Patent Valor and research funding from Novartis. TAT reports speaking fees from Abbvie and Roche-Chuga\u00ef.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}